News headlines about BioSpecifics Technologies Corp (NASDAQ:BSTC) have been trending somewhat positive recently, according to Accern Sentiment. The research group rates the sentiment of news coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. BioSpecifics Technologies Corp earned a news sentiment score of 0.15 on Accern’s scale. Accern also assigned news articles about the biopharmaceutical company an impact score of 45.4045101152445 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

A number of equities analysts have recently commented on BSTC shares. HC Wainwright set a $72.00 price objective on BioSpecifics Technologies Corp and gave the stock a “buy” rating in a research report on Thursday, August 10th. BidaskClub downgraded BioSpecifics Technologies Corp from a “sell” rating to a “strong sell” rating in a report on Friday, August 18th. Finally, Zacks Investment Research downgraded BioSpecifics Technologies Corp from a “hold” rating to a “strong sell” rating in a report on Friday, August 11th.

BioSpecifics Technologies Corp (NASDAQ:BSTC) traded down 0.47% on Friday, reaching $46.16. The company’s stock had a trading volume of 21,446 shares. BioSpecifics Technologies Corp has a 52-week low of $41.00 and a 52-week high of $58.79. The firm has a 50-day moving average price of $46.68 and a 200 day moving average price of $50.85. The firm has a market capitalization of $330.69 million, a P/E ratio of 28.32 and a beta of 1.76.

TRADEMARK VIOLATION NOTICE: “Somewhat Favorable News Coverage Somewhat Unlikely to Affect BioSpecifics Technologies Corp (BSTC) Stock Price” was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece on another publication, it was illegally copied and republished in violation of US and international copyright & trademark law. The original version of this piece can be accessed at

BioSpecifics Technologies Corp Company Profile

BioSpecifics Technologies Corp. is a biopharmaceutical company involved in the development of an injectable collagenase clostridium histolyticum for multiple indications. The Company has a development and license agreement with Endo Global Ventures, a Bermuda unlimited liability company (Endo Global Ventures), an affiliate of Endo International plc (Endo), for injectable collagenase for marketed indications and indications in development.

Insider Buying and Selling by Quarter for BioSpecifics Technologies Corp (NASDAQ:BSTC)

Receive News & Stock Ratings for BioSpecifics Technologies Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioSpecifics Technologies Corp and related stocks with our FREE daily email newsletter.